Xenon and Genentech Ink Rx, Companion Dx Collaboration and License Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian drug discovery firm Xenon said this week that it will collaborate with Genentech to discover and develop compounds and companion diagnostics for treating pain.

The pact could bring Burnaby, BC-based Xenon up to $646 million in total payments.

The agreement gives Genentech a non-exclusive license to develop and commercialize diagnostics developed under the collaboration and an exclusive license to compounds, Xenon said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.